ArticleLupus science & medicine2026
Measurements of urinary biomarkers at 2 years following a lupus nephritis flare are associated with subsequent renal outcomes.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine if the levels of five urinary biomarkers (UBs), including cluster of differentiation 163 (CD163), monocyte chemoattractant protein-1 (MCP-1), adiponectin, soluble vascular cell adhesion molecule and platelet factor 4 (PF4), measured 24 months after a lupus nephritis (LN) flare are associated with adverse long-term outcomes.
methodsWe included patients with an LN flare who had a preflare estimated glomerular filtration rate (eGFR) ≥60 mL/min and stored urine 24±3 months after the flare. The following outcomes were then examined: (1) time to a subsequent LN flare and (2) time to 30% sustained decline in eGFR. UBs were measured by ELISA 24±3 months after the LN flare. The results were normalised to urine creatinine and expressed as pg per mmol of urine creatinine.
results69 patients with LN were included, the median (IQR) follow-up time after their 24-month urinary sample collection was 129 (97.5-150) months. 50 patients achieved a primary efficacy renal response 24 months after the LN flare. This subcohort of patients had significantly lower UB levels. In this subcohort, 27 (54%) experienced a subsequent LN flare with a median time to flare (IQR) of 3.5 (1.67-6.87) years, and 10 (20%) had a 30% decline in eGFR at a median time of 4.38 (3.73-5.33) years after their 24-month urinary sample collection. Elevated levels of MCP-1 (HR 1.40 (1.11-1.76), p=0.004) and CD163 (HR 1.14 (1.00-1.38), p=0.01) predicted a subsequent LN flare. While CD163 (HR 1.16 (1.02-1.32), p=0.02), MCP-1 (HR 1.33 (1.01-1.74), p=0.04), adiponectin (HR 2.67 (1.68-2.46), p<0.001) and PF4 (HR 1.14 (1.04-1.25), p=0.002) predicted a 30% decline in eGFR.
conclusionUBs measured 24±3 months after an LN flare were associated with subsequent flares and a clinically meaningful decline in kidney function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.